Money and Medicines: An Economic Analysis of Reference Pricing and Related Public-sector Cost-containment Systems for Pharmaceuticals with Special Reference to New Zealand, by Alan Woodfield, John Fountain and Pim Borren (a review)
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- Sara Ellison Fisher & Iain Cockburn & Zvi Griliches & Jerry Hausman, 1997.
"Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins,"
RAND Journal of Economics, The RAND Corporation, vol. 28(3), pages 426-446, Autumn.
- Ellison, S & Cockburn, I & Griliches, A & Hausman, J, 1996. "Characteristics of Demand for Pharmaceutical Products : an Examination of four Cephalosporins," Working papers 96-24, Massachusetts Institute of Technology (MIT), Department of Economics.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Hostenkamp, Gisela, 2013. "Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector," Health Policy, Elsevier, vol. 111(1), pages 68-77.
- Tomaso Duso & Annika Herr & Moritz Suppliet, 2014.
"The Welfare Impact Of Parallel Imports: A Structural Approach Applied To The German Market For Oral Anti‐Diabetics,"
Health Economics, John Wiley & Sons, Ltd., vol. 23(9), pages 1036-1057, September.
- Duso, T. & Herr, A. & Suppliet, M, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics," Health, Econometrics and Data Group (HEDG) Working Papers 14/09, HEDG, c/o Department of Economics, University of York.
- Tomaso Duso & Annika Herr & Moritz Suppliet, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-Diabetics," Discussion Papers of DIW Berlin 1373, DIW Berlin, German Institute for Economic Research.
- Duso, Tomaso & Herr, Annika & Suppliet, Moritz, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics," DICE Discussion Papers 137, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
- Suppliet, Moritz & Duso, Tomaso & Herr, Annika, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral antidiabetics," VfS Annual Conference 2014 (Hamburg): Evidence-based Economic Policy 100298, Verein für Socialpolitik / German Economic Association.
- Farasat A.S. Bokhari, 2013.
"What Is The Price Of Pay-To-Delay Deals?,"
Journal of Competition Law and Economics, Oxford University Press, vol. 9(3), pages 739-753.
- Farasat A.S. Bokhari, 2013. "What is the price of pay-to-delay deals?," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2013-01, Centre for Competition Policy, University of East Anglia, Norwich, UK..
- Rika Onishi Mortimer, 1998. "Demand for Prescription Drugs: The Effects of Managed Care Pharmacy Benefits," HEW 9802002, University Library of Munich, Germany.
- Lewis Evans & Neil Quigley & Sayeeda Bano & Nancy Devlin & Alireza Tourani Rad, 1998. "Book reviews," New Zealand Economic Papers, Taylor & Francis Journals, vol. 32(1), pages 83-103.
- Erik Canton & Ed Westerhout, 1999. "A model for the Dutch pharmaceutical market," Health Economics, John Wiley & Sons, Ltd., vol. 8(5), pages 391-402, August.
- Avi Dor & William Encinosa, 2010. "How Does Cost‐Sharing Affect Drug Purchases? Insurance Regimes in the Private Market for Prescription Drugs," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 19(3), pages 545-574, September.
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011.
"Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment,"
Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 624-638, August.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series 3258, CESifo.
- Farasat A.S. Bokhari & Franco Mariuzzo & Weijie Yan, 2019. "Antibacterial resistance and the cost of affecting demand: the case of UK antibiotics," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2019-03, Centre for Competition Policy, University of East Anglia, Norwich, UK..
- Guofang Huang & Matthew Shum & Wei Tan, 2019. "Is pharmaceutical detailing informative? Evidence from contraindicated drug prescriptions," Quantitative Marketing and Economics (QME), Springer, vol. 17(2), pages 135-160, June.
- Ivan Moreno-Torres, 2011. "Generic drugs in Spain: price competition vs. moral hazard," Working Papers XREAP2011-04, Xarxa de Referència en Economia Aplicada (XREAP), revised May 2011.
- Jing Wu & Judy Xu & Gordon Liu & Jiuhong Wu, 2014. "Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals," PharmacoEconomics, Springer, vol. 32(3), pages 293-303, March.
- Iain M. Cockburn & Scott Stern & Jack Zausner, 2011. "Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Energy R&D," NBER Chapters, in: Accelerating Energy Innovation: Insights from Multiple Sectors, pages 113-157, National Bureau of Economic Research, Inc.
- Richard T. Thakor & Andrew W. Lo, 2015. "Competition and R&D Financing Decisions: Theory and Evidence from the Biopharmaceutical Industry," NBER Working Papers 20903, National Bureau of Economic Research, Inc.
- Filippini, M. & Masiero, G. & Moschetti, K., 2009. "Regional consumption of antibiotics: A demand system approach," Economic Modelling, Elsevier, vol. 26(6), pages 1389-1397, November.
- Stern, S. & Trajtenberg, M., 1998.
"Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking,"
Papers
24-98, Tel Aviv.
- Scott Stern & Manuel Trajtenberg, 1998. "Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking," NBER Working Papers 6851, National Bureau of Economic Research, Inc.
- Panle Jia & Pinelopi K. Goldberg & Shubham Chaudhuri, 2006.
"Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India,"
American Economic Review, American Economic Association, vol. 96(5), pages 1477-1514, December.
- Shubham Chaudhuri & Pinelopi K. Goldberg & Panle Jia, 2003. "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India," NBER Working Papers 10159, National Bureau of Economic Research, Inc.
- Shubham Chaudhuri, 2006. "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India," Working Papers id:772, eSocialSciences.
- Aysegul Timur & Gabriel Picone & Jeffrey DeSimone, 2011.
"Has the European union achieved a single pharmaceutical market?,"
International Journal of Health Economics and Management, Springer, vol. 11(4), pages 223-244, December.
- Aysegul Timur & Gabriel Picone & Jeffrey S. DeSimone, 2010. "Has the European Union Achieved a Single Pharmaceutical Market?," NBER Working Papers 16261, National Bureau of Economic Research, Inc.
- Niklas Rudholm, 2003. "Competition and substitutability in the Swedish pharmaceuticals market," Applied Economics, Taylor & Francis Journals, vol. 35(14), pages 1609-1617.
- Dalen, Dag Morten & Sorisio, Enrico & Strøm, Steinar, 2009.
"Choosing among Competing Blockbusters: Does the Identity of the Third-party Payer Matter for Prescribing Doctors?,"
Memorandum
10/2009, Oslo University, Department of Economics.
- Dag Morten Dalen & Enrico Sorisio & Steinar Strøm, 2010. "Choosing among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?," CESifo Working Paper Series 3227, CESifo.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:vuw:vuwcsr:19040. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Library Technology Services (email available below). General contact details of provider: https://edirc.repec.org/data/fcvuwnz.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.